Clermont-Ferrand’s CHU has been utilizing robotic-assisted surgery for prostate cancer treatments for three years, enhancing precision and patient recovery. Annually diagnosing 60,000 new cases, this innovative approach allows surgeons to operate with improved visibility and control, reducing postoperative complications significantly. Dr. Clémentine Millet emphasizes that patients experience fewer side effects compared to traditional surgery. Feedback from patients like Jean highlights the reduced incision size and quicker recovery times, enabling many to leave the hospital within two days. As the hospital performs 70 robotic procedures yearly, mortality rates for prostate cancer continue to decline.